Status:
COMPLETED
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Lead Sponsor:
University Hospital, Tours
Conditions:
Non Small Cell Lung Cancer
Bladder Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Non-small cell lung cancer (NSCLC) is the most common histological form, accounting for 85% of all bronchopulmonary cancers (PBC). The advent of Immunity Checkpoint Inhibitors (ICIs) targeting Program...
Detailed Description
Non-small cell lung cancer (NSCLC) is the most common histological form, accounting for 85% of all bronchopulmonary cancers (PBC). The advent of Immunity Checkpoint Inhibitors (ICIs) targeting Program...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old
- Patients treated with immune checkpoint inhibitor alone or in combination with chemotherapy in 1st or 2nd line
- Patient with locally advanced or metastatic Non-Small-Cell Lung Cancer, or bladder cancer or Ear Nose Throat cancer
- Maximum delay of 2 months between ICI and chemotherapy
Exclusion
- Symptomatic brain metastases
- Corticotherapy \> 10 mg/day
- Active auto-immune disease
- Oncogenic addiction
- Data processing objection
Key Trial Info
Start Date :
September 3 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 29 2022
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT04487457
Start Date
September 3 2021
End Date
September 29 2022
Last Update
April 6 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical oncology department, University Hospital, Tours
Tours, France, 37044
2
Pneumology department, University Hospital, Tours
Tours, France, 37044